Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker VSTM
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | State Street Corporation | 4.02M | 4.4% | SCHEDULE 13G ↗ |
| Oct 30, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Vanguard Capital Management | 4.38M | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Steven Boyd | 7.02M | 7.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Armistice Capital, LLC | 7.02M | 7.8% | SCHEDULE 13G/A ↗ |
| Aug 7, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | State Street Corporation | 5.13M | 5.8% | SCHEDULE 13G ↗ |
| Jul 31, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | Vanguard Capital Management | 4.42M | 5.0% | SCHEDULE 13G ↗ |
| Jul 30, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | BlackRock, Inc. | 6.19M | 7.0% | SCHEDULE 13G/A ↗ |
| Jul 8, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Polar Capital Funds PLC - Biotechnology Fund | 3.70M | 4.8% | SCHEDULE 13G/A ↗ |
| Jul 8, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Polar Capital LLP | 3.70M | 4.8% | SCHEDULE 13G/A ↗ |
| Jul 8, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Polar Capital Holdings Plc | 3.70M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Roderick Wong | 9.02M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | RTW Investments, LP | 9.02M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Dmitry Balyasny | 1.36M | 1.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Dames GP LLC | 1.36M | 1.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Balyasny Asset Management Holdings LP | 1.36M | 1.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Bam GP LLC | 1.36M | 1.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Balyasny Asset Management L.P. | 1.36M | 1.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Steven Boyd | 4.59M | 5.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Armistice Capital, LLC | 4.59M | 5.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | James B. Tananbaum | 3.15M | 3.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Foresite Capital Management VI LLC | 3.15M | 3.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Foresite Capital Fund VI LP | 3.15M | 3.6% | SCHEDULE 13G/A ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Roderick Wong | 7.84M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | RTW Investments, LP | 7.84M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Dmitry Balyasny | 4.77M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Dames GP LLC | 4.77M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Balyasny Asset Management Holdings LP | 4.77M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Bam GP LLC | 4.77M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Balyasny Asset Management L.P. | 4.77M | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | Steven Boyd | 3.54M | 5.3% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | Armistice Capital, LLC | 3.54M | 5.3% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Steven A. Cohen | 995,026 | 1.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Point72 Capital Advisors, Inc. | 995,026 | 1.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Point72 Asset Management, L.P. | 995,026 | 1.3% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Daniel Mack | 3.80M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Wilmot B. Harkey | 3.80M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Nantahala Capital Management, LLC | 3.80M | 4.7% | SCHEDULE 13G/A ↗ |
| Jan 5, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | Polar Capital Funds PLC - Biotechnology Fund | 3.40M | 5.1% | SCHEDULE 13G ↗ |
| Jan 5, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | Polar Capital LLP | 3.40M | 5.1% | SCHEDULE 13G ↗ |
| Jan 5, 2026 | SCHEDULE 13G | VSTM Verastem, Inc. | Polar Capital Holdings Plc | 3.40M | 5.1% | SCHEDULE 13G ↗ |
| Nov 21, 2025 | SCHEDULE 13G | VSTM Verastem, Inc. | David Kroin | 7.72M | 10.0% | SCHEDULE 13G ↗ |
| Nov 21, 2025 | SCHEDULE 13G | VSTM Verastem, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 7.72M | 10.0% | SCHEDULE 13G ↗ |
| Nov 21, 2025 | SCHEDULE 13G | VSTM Verastem, Inc. | Deep Track Capital, LP | 7.72M | 10.0% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Dmitry Balyasny | 5.72M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Dames GP LLC | 5.72M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Balyasny Asset Management Holdings LP | 5.72M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Bam GP LLC | 5.72M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Balyasny Asset Management L.P. | 5.72M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VSTM Verastem, Inc. | Daniel Mack | 4.63M | 7.1% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances